Skip to content

Depreciation at other companies

Ionis Pharmaceuticals logo
Ionis PharmaceuticalsIONS
Axsome Therapeutics logo
Axsome TherapeuticsAXSM
Summit Therapeutics logo
Summit TherapeuticsSMMT
Gilead Sciences logo
Gilead SciencesGILD

Other financials

Income statement

See full
Revenue$1.1B+19.1%
Operating income$336.6M+702%
Net income$293.1M+417%
EPS (diluted)$4.43+391%

Balance sheet

See full
Cash & equivalents$667.5M-64.1%
Total debt$5.4B-0.1%
Total equity$4.5B+8.6%
Total assets$11.9B+2.8%

Cash flow

See full
Operating cash flow$408.2M-5.0%
CapEx$19.7M+41.7%
Free cash flow$388.5M-6.6%

Valuation

See full
Market cap$14.11B+54.4%
Enterprise value$18.85B+47.7%
P/S3.2×+0.9×

Profitability

See full
Operating margin-11.9%-28.1pp
Net margin-8.9%-20.5pp
FCF margin28.6%-8.6pp

Returns & leverage

See full
Return on equity-9.1%-21.2pp
Debt / equity1.2×-0.1×
Current ratio-1.3×

Where this comes from

Reported directly by Jazz Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:Depreciation.

The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about Jazz Pharmaceuticals's depreciation.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Jazz Pharmaceuticals's depreciation?
Jazz Pharmaceuticals (JAZZ) reported depreciation of $9.1M in Q1 2026.
How has Jazz Pharmaceuticals's depreciation changed year-over-year?
Jazz Pharmaceuticals's depreciation decreased by 12.5% year-over-year, from $10.4M to $9.1M.
What is the long-term trend for Jazz Pharmaceuticals's depreciation?
Over 4 years (2021 to 2025), Jazz Pharmaceuticals's depreciation has grown at a 11.7% compound annual growth rate (CAGR), from $26.71M to $41.64M.